Hormonal Disorders

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

The FDA approves hydrocortisone oral solution for pediatric adrenal insufficiency, enhancing dosing accuracy and ease for young patients and caregivers.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

Chronic hypoparathyroidism requires holistic management addressing more than just calcium normalization to achieve optimal patient outcomes.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

Testosterone replacement therapy did not differ significantly from placebo in preventing diabetes progression in a substudy of the TRAVERSE randomized trial.

Fracture occurrences were numerically higher among men who received testosterone than placebo across a subtrial of the phase 4 TRAVERSE trial.

A phase 4 trial of men with hypogonadism in the US offers an overview of the potential risk of major cardiovascular events associated with use of testosterone replacement therapy.

Announced on May 1, the CRL from the FDA expressed concerns related to manufacturing control strategy, but did not express concern related to clinical data submitted as part of the NDA package for TransCon PTH.

In what investigators are calling the largest study of its kind ever conducted in the US, results of the 2-year study, which included more than 300 transgender or nonbinary youth, underline the positive benefits seen with receipt of gender-affirming hormone therapy among this patient population.

Published on November 1, the USPSTF reaffirmed their stance against use of hormone therapy for primary prevention of chronic conditions in postmenopausal persons, which was the stance the organization took in their 2017 recommendations.

A systematic review of studies published from 1998-2021 provides insight into the potential long-term quality of life improvements achieved after undergoing parathyroidectomy in patients who primary hyperparathyroidism, with results shedding light on the quality of life changes up to 10 years after parathyroidectomy.

An analysis of more than 11 million women in China details associations between preconception thyroid dysfunction, measured as thyrotropin levels, and delayed time to pregnancy and risk of spontaneous abortion.

New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.

Our endocrinology month in review spotlights the most popular content from the past month. The top content from July includes hormone therapy guidance from NAMS, a comparison of management practices among Medicare beneficiaries, and a recap of the top approvals from the first half of 2022.

An analysis of data from more than 8400 postmenopausal women with a history of early-stage nonmetastatic, ER-positive breast cancer suggests there was no increase in risk of breast cancer recurrence or mortality observed with use of vaginal estrogen therapy or menopausal hormone therapy.

A study of more than 15,000 patients from a national insurance research database suggests older patients with hypothyroidism had an 81% increase in risk of having dementia compared to their counterparts without hypothyroidism.

Dr. Gregory Weiss examines a recent study that detailed the risk of cardiovascular disease associated with under- and over-treatment with thyroid hormone therapy.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.

A systematic review and meta-analysis from AACE 2022 provides an overview of the potential associations between thyroid dysfunction, including both hypothyroidism and hyperthyroidism, and risk of Parkinson disease.

Data presented at AACE 2022 detail levoketoconazole-specific effects observed among patients with endogenous Cushing's syndrome from the phase 3 LOGICS trial.

A retrospective cohort study provides evidence suggesting higher TSH levels were linked to increased lengths of stay and greater readmission risks among patients with hypothyroidism.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

An analysis of nationwide data from Sweden provides an overview of the increased risk of death associated with Cushing's disease was present even after biochemical remission.